Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy : Model-based dose optimization
© 2024 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)..
The pharmacological activity of oxcarbazepine (OXC) is primarily exerted through its active 10-monohydroxy metabolite (MHD). Nonetheless, there is limited pharmacokinetic information available regarding paediatric patients with epilepsy treated with OXC, especially in infants and toddlers. Concurrently, this drug exhibits substantial variability in pharmacokinetics and therapeutic response across different individuals. We aimed to develop a model to quantitatively investigate factors that affect MHD pharmacokinetics to formulate a dosage guideline for OXC in Chinese paediatric patients. A total of 297 MHD trough concentrations were obtained from 287 epileptic children. Six body weight (BW)-based allometric models were used for population pharmacokinetic modelling, while investigating the impact of other covariates on the apparent clearance. The one-compartment model and age cut-off model for the apparent clearance (CL/F) were established to describe the pharmacokinetics of MHD. The probability to obtain target trough concentration ranges (TTCRs) of MHD between 3 and 35 mg/L was determined by Monte Carlo simulations for doses ranging from 8 to 90 mg/kg/day. A new dose optimization strategy combining the dosage guidelines and Bayesian method provides a tailored approach for Chinese paediatric epileptic patients based on their individual BW and desired TTCRs of MHD, and also supports current dose recommendations, with the exception of children weighing ≤5 kg.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
|---|---|
| Enthalten in: |
Basic & clinical pharmacology & toxicology - 134(2024), 5 vom: 16. Apr., Seite 712-726 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
33CM23913M |
|---|
| Anmerkungen: |
Date Completed 17.04.2024 Date Revised 17.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcpt.14000 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369959701 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369959701 | ||
| 003 | DE-627 | ||
| 005 | 20240417232704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcpt.14000 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM369959701 | ||
| 035 | |a (NLM)38506371 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric patients with epilepsy |b Model-based dose optimization |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). | ||
| 520 | |a The pharmacological activity of oxcarbazepine (OXC) is primarily exerted through its active 10-monohydroxy metabolite (MHD). Nonetheless, there is limited pharmacokinetic information available regarding paediatric patients with epilepsy treated with OXC, especially in infants and toddlers. Concurrently, this drug exhibits substantial variability in pharmacokinetics and therapeutic response across different individuals. We aimed to develop a model to quantitatively investigate factors that affect MHD pharmacokinetics to formulate a dosage guideline for OXC in Chinese paediatric patients. A total of 297 MHD trough concentrations were obtained from 287 epileptic children. Six body weight (BW)-based allometric models were used for population pharmacokinetic modelling, while investigating the impact of other covariates on the apparent clearance. The one-compartment model and age cut-off model for the apparent clearance (CL/F) were established to describe the pharmacokinetics of MHD. The probability to obtain target trough concentration ranges (TTCRs) of MHD between 3 and 35 mg/L was determined by Monte Carlo simulations for doses ranging from 8 to 90 mg/kg/day. A new dose optimization strategy combining the dosage guidelines and Bayesian method provides a tailored approach for Chinese paediatric epileptic patients based on their individual BW and desired TTCRs of MHD, and also supports current dose recommendations, with the exception of children weighing ≤5 kg | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bayesian | |
| 650 | 4 | |a epilepsy | |
| 650 | 4 | |a oxcarbazepine active metabolite | |
| 650 | 4 | |a paediatric patient | |
| 650 | 4 | |a population pharmacokinetic | |
| 650 | 7 | |a Oxcarbazepine |2 NLM | |
| 650 | 7 | |a VZI5B1W380 |2 NLM | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Carbamazepine |2 NLM | |
| 650 | 7 | |a 33CM23913M |2 NLM | |
| 700 | 1 | |a Yang, Wen-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xiao-Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Ge, Xi-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jinmiao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Guang-Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhi-Ping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Basic & clinical pharmacology & toxicology |d 2004 |g 134(2024), 5 vom: 16. Apr., Seite 712-726 |w (DE-627)NLM144330768 |x 1742-7843 |7 nnns |
| 773 | 1 | 8 | |g volume:134 |g year:2024 |g number:5 |g day:16 |g month:04 |g pages:712-726 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcpt.14000 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 134 |j 2024 |e 5 |b 16 |c 04 |h 712-726 | ||